Get the Stockscreener App
0.894
16.50%
-0.166
Humacyte Inc stock is traded at $0.894, with a volume of 25.66M.
It is down -16.50% in the last 24 hours and down -23.03% over the past month.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
See More
Previous Close:
$1.06
Open:
$0.976
24h Volume:
25.66M
Relative Volume:
4.78
Market Cap:
$173.08M
Revenue:
$1.57M
Net Income/Loss:
$-39.34M
P/E Ratio:
-3.7437
EPS:
-0.2388
Net Cash Flow:
$-106.40M
1W Performance:
-22.36%
1M Performance:
-23.03%
6M Performance:
-52.41%
1Y Performance:
-73.26%
1-Day Range:
$0.81
$0.98
1-Week Range:
$0.81
$1.22
52-Week Range:
$0.81
$3.36
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte Inc
Sector
Industry
Phone
919-313-9633
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
0.8968 | 204.58M | 1.57M | -39.34M | -106.40M | -0.2388 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.54 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.00 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
680.44 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.02 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
281.47 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-27-25 | Initiated | Barclays | Overweight |
| May-14-25 | Resumed | H.C. Wainwright | Buy |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-11-23 | Initiated | H.C. Wainwright | Buy |
| Aug-14-23 | Upgrade | Piper Sandler | Underweight → Neutral |
| Jun-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-22 | Downgrade | Piper Sandler | Overweight → Underweight |
| Oct-29-21 | Initiated | Cowen | Outperform |
| Sep-24-21 | Initiated | Oppenheimer | Outperform |
| Sep-22-21 | Initiated | BTIG Research | Buy |
| Sep-16-21 | Initiated | Piper Sandler | Overweight |
View All
Humacyte Inc Stock (HUMA) Latest News
Humacyte Ends ATM Program, Highlights Symvess Global Expansion - TipRanks
Saudi hospitals to evaluate Humacyte vessel under $1.475M deal - Stock Titan
Humacyte raises $20M to back Symvess launch and Phase 3 readout - Stock Titan
Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know - MSN
Humacyte submits marketing application for Symvess in Israel By Investing.com - Investing.com South Africa
Risk Hedge: What is the long term forecast for Humacyte Inc stockWeekly Investment Report & Scalable Portfolio Growth Methods - baoquankhu1.vn
Humacyte stock rating reiterated at Buy by D. Boral Capital - Investing.com
Humacyte submits marketing application for Symvess in Israel - Investing.com
Humacyte Submits Marketing Authorization Application for Symvess in Israel for Vascular Trauma Repair - Bitget
Humacyte (NASDAQ:HUMA) Given Buy Rating at D. Boral Capital - MarketBeat
Battlefield-tested trauma vessel targets Israeli hospitals next - Stock Titan
Humacyte, Senseonics jump as Barclays issues new Overweight ratings - MSN
Humacyte, Inc. (NASDAQ:HUMA) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Market Recap: Whats the fair value of Humacyte Inc Equity Warrant stock2026 Review & Community Driven Trade Alerts - baoquankhu1.vn
Aug Macro: What are Humacyte Inc Equity Warrants technical support levels2026 Risk Factors & Weekly High Momentum Picks - baoquankhu1.vn
Humacyte at Barclays Conference: Strategic Insights and Future Plans By Investing.com - Investing.com Canada
Risk Analysis: Will Humacyte Inc benefit from rising consumer demandQuarterly Trade Summary & Safe Entry Zone Identification - baoquankhu1.vn
Institution Moves: Does Humacyte Inc have a sustainable dividend2026 Action & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Humacyte jumps as US legislation backs bioengineered vessels - MSN
Humacyte, Inc. (HUMA) Is Considered a Good Investment by Brokers: Is That True? - Yahoo Finance
Humacyte, Inc. (HUMA) Is Viewed Favorably by Analysts: Does This Hold Up? - Bitget
HUMA Stock Is Soaring Today – Here’s Everything To Know About The DOD Funding Fueling The Surge - Stocktwits
Humacyte at TD Cowen Conference: Strategic Advances in Vascular Care By Investing.com - Investing.com Canada
Bioengineered tissue firm Humacyte lines up back-to-back March investor talks - Stock Titan
HUMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Humacyte, Inc. to Contact the Firm Today! - ACCESS Newswire
US Stocks Recap: Can Humacyte Inc sustain its profitabilityTrend Reversal & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Humacyte To Participate in Upcoming Investor Conferences - Bitget
Levels Update: What is the long term forecast for Humacyte Inc stock2025 Earnings Impact & Fast Moving Market Watchlists - baoquankhu1.vn
Humacyte, Inc. (HUMA) Stock Analysis: Unveiling a Potential 527% Upside with Innovative Biotech Solutions - DirectorsTalk Interviews
HUMA Should I Buy - Intellectia AI
HUMA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Humacyte, Inc. $HUMA Shares Sold by CenterBook Partners LP - MarketBeat
Will Humacyte Inc. Equity Warrant face regulatory challengesWeekly Gains Report & Free Community Supported Trade Ideas - mfd.ru
What’s the fair value of Humacyte Inc. stock2025 Geopolitical Influence & Short-Term High Return Ideas - mfd.ru
Why Humacyte Inc. stock is favored by top institutions2025 Retail Activity & Fast Gaining Stock Strategy Reports - mfd.ru
Humacyte, Inc. (HUMA) Stock Analysis: Unpacking A 570% Potential Upside - DirectorsTalk Interviews
Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet - MSN
D. Boral Capital Reiterates Buy Rating for Humacyte (NASDAQ:HUMA) - MarketBeat
Insider Trends: Should I invest in Humacyte Inc Equity Warrant before earningsJuly 2025 Short Interest & Verified Stock Trade Ideas - baoquankhu1.vn
Humacyte Announces Presentation of Symvess Long-Term Safety and Efficacy Results at VESS Meeting - Bitget
Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting - The Manila Times
Hedge Fund Moves: Can Humacyte Inc deliver consistent EPS growthTrade Ideas & Accurate Trade Setup Notifications - baoquankhu1.vn
Humacyte (HUMA) Valuation Check As DoD Funding Highlights Symvess Battlefield Trauma Potential - Yahoo Finance
Humacyte Shares Surge on US Defense Funding News - StocksToTrade
Humacyte, Inc. (NASDAQ:HUMA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Humacyte promotes critical role of vascular health in February - Traders Union
Is Humacyte Inc. backed by strong institutional buyingWeekly Trade Recap & Proven Capital Preservation Methods - mfd.ru
Surprises Report: Whats the fair value of Humacyte Inc stock2025 Year in Review & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Chart Watch: Why Humacyte Inc. Equity Warrant stock remains on buy listsRate Hike & Reliable Breakout Forecasts - mfd.ru
Can Humacyte Inc. sustain earnings growthQuarterly Trade Review & High Conviction Investment Ideas - mfd.ru
Does Humacyte Inc. Equity Warrant stock benefit from AI growth2025 Sector Review & Free Risk Controlled Daily Trade Plans - mfd.ru
Humacyte Inc Stock (HUMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.42%
1.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):